Work

716. Durable Acute Myeloid Leukemia Remission Without Myeloablation in an Innovative Xenotolerant Mouse Model of CD44v6 CAR-T Cell Immunotherapy

Year: 2015

Type: article

Abstract: Despite the remarkable clinical results of chimeric antigen receptor (CAR) T-cell immunotherapy in B-cell tumors, its long-term success is limited by the emergence of CD19-loss tumor escape variants. We have developed a CD28-endocostimulated CD44v6 CAR for the targeting of multiple tumors, including acute myeloid leukemia (AML), multiple myeloma and epithelial cancers. Besides its widespread tumor expression, the appeal of CD44v6 as a CAR target stems from its non-redundant role in tumor progression and absent expression on hematopoietic stem cells (HSCs).

Source: Molecular Therapy

DOI: 10.1016/s1525-0016(16)34325-8